Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.

Chunxiao He, Beibei Zhang, Xinmin Yu, Zhengbo Song, Yiping Zhang, Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. Journal of Thoracic Disease. ,vol. 5, pp. 400- 405 ,(2013) , 10.3978/J.ISSN.2072-1439.2013.07.28

L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003

Jin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, Xu-Chao Zhang, Qing Zhou, Jian Su, Zhen Wang, Chong-Rui Xu, Yi-Sheng Huang, Bin-Chao Wang, Xue-Ning Yang, Wen-Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Ben-Yuan Jiang, Song Dong, Yi-Long Wu, Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer Lung Cancer. ,vol. 79, pp. 33- 39 ,(2013) , 10.1016/J.LUNGCAN.2012.09.016

Young Hak Kim, Akiko Fukuhara, Michiaki Mishima, Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease? Case Reports in Oncology. ,vol. 4, pp. 470- 474 ,(2011) , 10.1159/000332758

Kenichi Nishie, Tomoya Kawaguchi, Akihiro Tamiya, Tomoyasu Mimori, Naoko Takeuchi, Yoshinobu Matsuda, Naoki Omachi, Kazuhiro Asami, Kyoichi Okishio, Shinji Atagi, Tomohisa Okuma, Akihito Kubo, Yoshihito Maruyama, Shinzoh Kudoh, Minoru Takada, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations Journal of Thoracic Oncology. ,vol. 7, pp. 1722- 1727 ,(2012) , 10.1097/JTO.0B013E31826913F7

Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay, Conrad Lewanski, Stephen Falk, Geraldine Skailes, Ernie Marshall, Penella J Woll, Matthew Hatton, Rohit Lal, Richard Jones, Elizabeth Toy, David Chao, Gary Middleton, Sue Bulley, Yenting Ngai, Robin Rudd, Allan Hackshaw, Chris Boshoff, First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial Lancet Oncology. ,vol. 13, pp. 1161- 1170 ,(2012) , 10.1016/S1470-2045(12)70412-6

Lingli Tu, Lan Sun, Re-challenge treatment of small-molecular inhibitors in NSCLC patients beyond progression. Journal of Thoracic Disease. ,vol. 4, pp. 647- 649 ,(2012) , 10.3978/J.ISSN.2072-1439.2012.10.14

D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim, Ravi Salgia, Panagiotis Fidias, Jeffrey A Engelman, Leena Gandhi, Pasi A Jänne, Daniel B Costa, Geoffrey I Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith Wilner, Jeffrey W Clark, Alice T Shaw, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncology. ,vol. 13, pp. 1011- 1019 ,(2012) , 10.1016/S1470-2045(12)70344-3

Satoshi Watanabe, Junta Tanaka, Takeshi Ota, Rie Kondo, Hiroshi Tanaka, Hiroshi Kagamu, Kosuke Ichikawa, Jun Koshio, Junko Baba, Takao Miyabayashi, Ichiei Narita, Hirohisa Yoshizawa, Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer. ,vol. 11, pp. 1- 7 ,(2011) , 10.1186/1471-2407-11-1

Hiromichi Matsuoka, Takayasu Kurata, Isamu Okamoto, Hiroyasu Kaneda, Kaoru Tanaka, Kazuhiko Nakagawa, Clinical Response to Crizotinib Retreatment After Acquisition of Drug Resistance Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2012.46.4305